Πλοήγηση ανά Θέμα "immunological antineoplastic agent"
Αποτελέσματα 1-5 από 5
-
Advancements in the Treatment of Cerebrovascular Complications of Cancer
(2020)Purpose of review: To present the new guidelines and therapeutic options regarding cerebrovascular complications of cancer, mainly ischemic stroke, cerebral venous thrombosis (CVT), and leptomeningeal carcinomatosis (LMC). ... -
Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach
(2019)Oncology is currently a sector of medical science with accelerated progress due to rapid technological development, the advancement in molecular biology, and the invention of many innovative therapies. Immunotherapy partially ... -
Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching
(2018)Purpose: With the introduction of biosimilars of anticancer monoclonal antibodies (mAbs) in oncology, physicians are potentially confronted with the question whether it is clinically adequate to switch patients who are ... -
-
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting
(2016)Background: We investigated the impact of PIK3CA and TP53 mutations and p53 protein status on the outcome of patients who had been treated with adjuvant anthracycline-taxane chemotherapy within clinical trials in the pre- ...